Efficacy of mepolizumab treatment in patients with chronic rhinosinusitis with nasal polyps: a single-centre, real-life study

医学 慢性鼻-鼻窦炎 鼻息肉 美波利祖马布 鼻窦炎 胃肠病学 内科学 外科 嗜酸性粒细胞 哮喘
作者
Mehmet Erdem Cakmak,Osman Ozan Yeğit
出处
期刊:Alergologia Polska - Polish Journal of Allergology [Termedia Sp. z.o.o.]
卷期号:10 (1): 52-56 被引量:2
标识
DOI:10.5114/pja.2023.125768
摘要

Introduction: The anti-interleukin (IL)-5 antibody mepolizumab has been used in the treatment of patients with uncontrolled severe eosinophilic asthma.Aim: In this real-life study, we aimed to evaluate the effect of mepolizumab on nasal symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).Material and methods: Adult patients (> 18 years old) with concomitant CRSwNP, who were treated with mepolizumab at a dose of 100 mg every 4 weeks for at least one year for severe eosinophilic asthma, between 2021 and 2022, were evaluated retrospectively.Asthma control testing (ACT), Sino-Nasal Outcome Test (SNOT-22), and a visual analogue scale (VAS) of 1 to 10 (from 1 to 10) for nasal symptoms were compared at baseline (pre-mepolizumab treatment), and at 6 and 12 months post-treatment.The need for endoscopic sinus surgery (ESS) and oral corticosteroid (OCS) was compared at 12 months pre-mepolizumab and post-mepolizumab treatment.Results: The mean age of the 18 patients (9 (50%) males and 9 (50%) females) was 42.33 ±15.9 years.Mepolizumab significantly reduced the number of endoscopic sinus surgeries (ESSs) (p = 0.002).The need for shortcourse oral corticosteroid (OCS) decreased significantly after mepolizumab treatment (p = 0.029).Statistically significant improvements were found in the ACT, SNOT-22, and nasal symptom scores at 6 and 12 months post-treatment when compared to baseline.No side effects were observed post-treatment.Conclusions: Mepolizumab improved nasal symptoms and reduced the need for OCS and ESS in patients with CRSwNP.However, the results obtained in the study should be confirmed with real-life studies involving larger numbers of patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Leo完成签到 ,获得积分10
刚刚
xcky0917发布了新的文献求助10
1秒前
Xu发布了新的文献求助10
3秒前
4秒前
超帅的勒完成签到,获得积分10
5秒前
巴黎没有摩天轮完成签到,获得积分10
6秒前
xcky0917完成签到,获得积分10
7秒前
Izzy完成签到,获得积分10
7秒前
贲孱完成签到,获得积分10
9秒前
123发布了新的文献求助10
9秒前
cata完成签到,获得积分10
11秒前
沐泽完成签到 ,获得积分10
13秒前
breaking完成签到 ,获得积分10
13秒前
ShishanXue完成签到 ,获得积分10
13秒前
rufus完成签到,获得积分10
14秒前
俏皮天德完成签到,获得积分10
14秒前
白桃战士完成签到,获得积分10
14秒前
行走的猫完成签到 ,获得积分10
15秒前
XBDM完成签到,获得积分10
15秒前
CHEN完成签到,获得积分10
15秒前
恋苳完成签到 ,获得积分10
16秒前
甜甜的紫菜完成签到 ,获得积分0
16秒前
赘婿的应助被Xu采纳,获得10
17秒前
辛勤的囧完成签到,获得积分10
17秒前
gcl完成签到,获得积分0
18秒前
ddd完成签到,获得积分10
18秒前
lst完成签到,获得积分10
19秒前
邹馥罄完成签到 ,获得积分10
20秒前
无极微光的应助被Junsir采纳,获得20
20秒前
甜甜纸飞机完成签到 ,获得积分10
21秒前
谦让小玉完成签到 ,获得积分10
21秒前
hualuo13完成签到,获得积分10
22秒前
御剑风形完成签到 ,获得积分10
22秒前
24秒前
七月完成签到,获得积分10
24秒前
朴素的荧荧完成签到,获得积分10
25秒前
zhen完成签到,获得积分20
25秒前
xx完成签到 ,获得积分10
25秒前
啊德哈卡完成签到,获得积分10
26秒前
平常的铅笔完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923